Article: Verdict still uncertain on tiagabine for insomnia.

DENVER -- The anticonvulsant tiagabine (Gabitril) increased slow-wave sleep in a dose-dependent fashion in a 30-center randomized trial involving 232 adults with primary insomnia, James K. Walsh, Ph.D., reported at the annual meeting of the Associated Professional Sleep Societies.

But whether this drug-induced alteration in sleep architecture will translate into clinical utility for the treatment of insomnia remains an unanswered question. Of note, patients given tiagabine didn't report their sleep as being any deeper, more refreshing, or of better quality than patients on placebo. Moreover, tiagabine did not affect total sleep time, latency to persistent sleep, ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!